Free Trial

Allurion Technologies (ALUR) Stock Forecast & Price Target

Allurion Technologies logo
$0.45 +0.04 (+9.69%)
(As of 11/20/2024 ET)

Allurion Technologies - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
1
Buy
4

Based on 5 Wall Street analysts who have issued ratings for Allurion Technologies in the last 12 months, the stock has a consensus rating of "Buy." Out of the 5 analysts, 1 has given a hold rating, 3 have given a buy rating, and 1 has given a strong buy rating for ALUR.

Consensus Price Target

$2.88
534.94% Upside
According to the 5 analysts' twelve-month price targets for Allurion Technologies, the average price target is $2.88. The highest price target for ALUR is $5.00, while the lowest price target for ALUR is $2.00. The average price target represents a forecasted upside of 534.94% from the current price of $0.45.
Get the Latest News and Ratings for ALUR and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Allurion Technologies and its competitors.

Sign Up

ALUR Analyst Ratings Over Time

TypeCurrent Forecast
11/22/23 to 11/21/24
1 Month Ago
10/23/23 to 10/22/24
3 Months Ago
8/24/23 to 8/23/24
1 Year Ago
11/22/22 to 11/22/23
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
N/A
Buy
3 Buy rating(s)
4 Buy rating(s)
2 Buy rating(s)
N/A
Hold
1 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
N/A
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
N/A
Consensus Price Target$2.88$2.88$3.75N/A
Forecasted Upside534.94% Upside287.31% Upside449.45% UpsideN/A
Consensus Rating
Buy
Buy
Buy
N/A

ALUR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ALUR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Allurion Technologies Stock vs. The Competition

TypeAllurion TechnologiesMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.80
2.50
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside534.94% Upside26,931.55% Upside9.81% Upside
News Sentiment Rating
Neutral News

See Recent ALUR News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/14/2024Chardan Capital
1 of 5 stars
K. Nakae
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
10/2/2024TD Cowen
4 of 5 stars
J. Jennings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$2.00+241.88%
9/6/2024Roth Capital
3 of 5 stars
J. Wittes
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
9/6/2024Roth Mkm
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$2.00+217.46%
2/9/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$5.00+68.92%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 05:50 AM ET.


ALUR Forecast - Frequently Asked Questions

According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for Allurion Technologies is $2.88, with a high forecast of $5.00 and a low forecast of $2.00.

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Allurion Technologies in the last twelve months. There is currently 1 hold rating, 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ALUR shares.

According to analysts, Allurion Technologies's stock has a predicted upside of 534.94% based on their 12-month stock forecasts.

Over the previous 90 days, Allurion Technologies's stock had 1 upgrade and 1 downgrade by analysts.

Allurion Technologies has been rated by research analysts at Chardan Capital, Roth Capital, Roth Mkm, and TD Cowen in the past 90 days.

Analysts like Allurion Technologies more than other "medical" companies. The consensus rating for Allurion Technologies is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ALUR compares to other companies.


This page (NYSE:ALUR) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners